Table 2.
Primary and secondary endpoints.
| SDE (n = 38) | Placebo (n = 40) | P value | |
|---|---|---|---|
| VAS AUC (0–48 h) | 116.0 ± 42.6 | 119.4 ± 41.6 | .395 |
| VAS AUC (0–24 h) | 66.0 ± 24.1 | 67.6 ± 23.3 | .499 |
| VAS AUC (24–48 h) | 50.1 ± 19.3 | 51.8 ± 19.4 | .514 |
| Highest VAS (0–48 h) | 4.0 ± 1.5 | 4.0 ± 1.7 | .893 |
| Average VAS (0–48 h) | 2.3 ± 0.7 | 2.6 ± 0.8 | .144 |
| NRS at 72 h | 2.1 ± 1.3 | 2.0 ± 1.1 | .912 |
| NRS at 7 d | 1.2 ± 1.2 | 1.0 ± 0.9 | .769 |
| Rescue analgesics | |||
| 0–24 h | 26 (68.4) | 29 (72.5) | .805 |
| 24–48 h | 3 (7.9) | 0 | .111 |
| CPSP at 90 d | 5 (13.1) | 9 (22.5) | .379 |
Data were analyzed using independent t test or Fisher exact test, as appropriate. Results are presented as n (%) or mean ± SD.
AUC = area under the curve, CPSP = chronic postsurgical pain, NRS = numerical rating scale, SDE = sebacoyl dinalbuphine ester, VAS = visual analog scale.